AbCellera Biologics Inc. reports results for the quarter ended June 30 - Earnings Summary
AbCellera Biologics Inc. reports results for the quarter ended June 30 - Earnings Summary
AbCellera Biologics Inc. ABCL.OQ reported a quarterly adjusted loss of 18 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of eight analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -20 cents to -1 cents per share.
Revenue fell 76.3% to $4.05 million from a year ago; analysts expected $7.78 million.
AbCellera Biologics Inc.'s reported EPS for the quarter was a loss of 18 cents.
The company reported a quarterly loss of $55.43 million.
AbCellera Biologics Inc. shares had fallen by 22.4% this quarter and gained 78.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 25.4% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for AbCellera Biologics Inc. is $11.00, about 46.2% above its last closing price of $5.92
This summary was machine generated from LSEG data August 5 at 11:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.14 | -0.18 | Missed |
Mar. 31 2026 | -0.20 | -0.14 | Beat |
Dec. 31 2025 | -0.17 | -0.03 | Beat |
Sep. 30 2025 | -0.17 | -0.19 | Missed |
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce